Associated Papers
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
Coding Variants of the FMO3 Gene Are Associated with the Risk of Chronic Kidney Disease: A Case-Control Study.
Shorudi Dadi I et al.
Reports of Biochemistry & Molecular Biology, 2022
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3.
Nguyen PTT et al.
Journal of Clinical Pharmacology, 2019
Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.
Bloom AJ et al.
Pharmacogenetics and Genomics, 2013
Flavin-containing monooxygenases: mutations, disease and drug response.
Phillips IR et al.
Trends in Pharmacological Sciences, 2008
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Genetic polymorphisms of flavin-containing monooxygenase (FMO).
Krueger SK et al.
Drug Metabolism Reviews, 2002
Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication.
Treacy EP et al.
Human Molecular Genetics, 1998
Select a paper to view details